Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1983 1
1987 2
1988 1
1989 1
1991 1
1992 1
1993 1
1994 1
1995 2
1996 3
1997 1
1998 4
2000 2
2001 2
2002 2
2003 6
2004 7
2005 8
2006 17
2007 11
2008 19
2009 21
2010 27
2011 36
2012 50
2013 44
2014 78
2015 75
2016 80
2017 110
2018 121
2019 87
2020 137
2021 129
2022 150
2023 119
2024 141
2025 192
2026 92

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,569 results

Results by year

Filters applied: . Clear all
Page 1
Moving urate-lowering therapy in gout beyond guideline recommendations.
Stamp LK, Dalbeth N. Stamp LK, et al. Semin Arthritis Rheum. 2024 Apr;65:152358. doi: 10.1016/j.semarthrit.2023.152358. Epub 2024 Jan 10. Semin Arthritis Rheum. 2024. PMID: 38219395 Free article. Review.
The 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rheumatology societies for many years. ...In this review we consider the rationale for the treat-to-target urate strategy when using urate …
The 'treat-to target serum urate strategy' when using urate-lowering therapy has been recommended by most specialist rh …
Combination urate-lowering therapy in the treatment of gout: What is the evidence?
Perez-Ruiz F, Dalbeth N. Perez-Ruiz F, et al. Semin Arthritis Rheum. 2019 Feb;48(4):658-668. doi: 10.1016/j.semarthrit.2018.06.004. Epub 2018 Jun 20. Semin Arthritis Rheum. 2019. PMID: 30075988 Review.
While the use of combination therapies has been investigated for many years, we reviewed data from the published studies to investigate the efficacy and safety of this approach. METHODS: Relevant published papers were identified by keyword search on PubMed and categorized …
While the use of combination therapies has been investigated for many years, we reviewed data from the published studies to investiga …
Effect of urate-lowering therapy on all-cause and CVD-specific mortality in gout and hyperuricemia: a meta-analysis.
Lee YH, Song GG. Lee YH, et al. Z Rheumatol. 2024 Dec;83(Suppl 3):338-344. doi: 10.1007/s00393-024-01600-0. Epub 2024 Dec 5. Z Rheumatol. 2024. PMID: 39636389 English.
OBJECTIVE: The aim of this study was to assess the relationships between urate-lowering therapy (ULT) and both all-cause and cardiovascular disease (CVD)-specific mortality in patients diagnosed with gout or hyperuricemia. ...
OBJECTIVE: The aim of this study was to assess the relationships between urate-lowering therapy (ULT) and both all-caus …
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
Stamp L, Dalbeth N. Stamp L, et al. Semin Arthritis Rheum. 2017 Feb;46(4):457-464. doi: 10.1016/j.semarthrit.2016.07.015. Epub 2016 Jul 28. Semin Arthritis Rheum. 2017. PMID: 27591828 Review.
OBJECTIVE: The observed associations of hyperuricaemia with hypertension, cardiovascular disease and kidney disease are receiving increasing interest. The potential role of urate-lowering therapy in the management of these "non-gout diseases" has been raised, …
OBJECTIVE: The observed associations of hyperuricaemia with hypertension, cardiovascular disease and kidney disease are receiving increasing …
Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes: A Systematic Review and Meta-Analysis.
Chen Q, Wang Z, Zhou J, Chen Z, Li Y, Li S, Zhao H, Badve SV, Lv J. Chen Q, et al. Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1576-1586. doi: 10.2215/CJN.05190420. Epub 2020 Oct 14. Clin J Am Soc Nephrol. 2020. PMID: 33055192 Free PMC article.
In this systematic review, we aimed to evaluate the efficacy of urate-lowering therapy on major adverse cardiovascular events, all-cause mortality, kidney failure events, BP, and GFR. ...There was no significant difference (risk ratio, 1.01; 95% confidence in …
In this systematic review, we aimed to evaluate the efficacy of urate-lowering therapy on major adverse cardiovascular …
Efficacy of initiating urate-lowering therapy during an acute gout episode: a meta-analysis.
Lee YH, Song GG. Lee YH, et al. Z Rheumatol. 2023 Nov;82(9):763-769. doi: 10.1007/s00393-023-01366-x. Epub 2023 May 26. Z Rheumatol. 2023. PMID: 37233824 Review. English.
OBJECTIVE: This study aimed to evaluate the effectiveness of initiating urate-lowering therapy (ULT) during acute gout episodes. METHODS: We performed a literature search using MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (from ince …
OBJECTIVE: This study aimed to evaluate the effectiveness of initiating urate-lowering therapy (ULT) during acute gout …
Gout.
Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Dalbeth N, et al. Nat Rev Dis Primers. 2019 Sep 26;5(1):69. doi: 10.1038/s41572-019-0115-y. Nat Rev Dis Primers. 2019. PMID: 31558729 Review.
Allopurinol is the first-line urate-lowering therapy and should be started at a low dose, with gradual dose escalation. Low-dose anti-inflammatory therapies can reduce gout flares during initiation of urate-lowering therapy. Models …
Allopurinol is the first-line urate-lowering therapy and should be started at a low dose, with gradual dose escalation. …
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review.
Beslon V, Moreau P, Maruani A, Maisonneuve H, Giraudeau B, Fournier JP. Beslon V, et al. J Gen Intern Med. 2018 Mar;33(3):358-366. doi: 10.1007/s11606-017-4233-5. Epub 2017 Dec 4. J Gen Intern Med. 2018. PMID: 29204974 Free PMC article.
BACKGROUND: Urate-lowering therapy (ULT) is associated with low rates of adherence, leading to a potential risk of relapse of gouty arthritis, tophi, or urolithiasis. ...METHODS: We conducted a systematic literature review of clinical studies investigating th …
BACKGROUND: Urate-lowering therapy (ULT) is associated with low rates of adherence, leading to a potential risk of rela …
Urate-lowering therapy: current options and future prospects for elderly patients with gout.
Stamp LK, Chapman PT. Stamp LK, et al. Drugs Aging. 2014 Nov;31(11):777-86. doi: 10.1007/s40266-014-0214-0. Drugs Aging. 2014. PMID: 25256017 Review.
Gout is increasingly seen in the elderly population, in large part due to physiological decline in renal function with age, and as a result of therapy for comorbidities, in particular the use of diuretic therapies for hypertension and congestive heart failure. Ur …
Gout is increasingly seen in the elderly population, in large part due to physiological decline in renal function with age, and as a result …
Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review.
Tabi-Amponsah AD, Stewart S, Hosie G, Stamp LK, Taylor WJ, Dalbeth N. Tabi-Amponsah AD, et al. Pharmaceuticals (Basel). 2023 May 23;16(6):779. doi: 10.3390/ph16060779. Pharmaceuticals (Basel). 2023. PMID: 37375727 Free PMC article. Review.
Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi. Thus, disea …
Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal …
1,569 results